



Current Research on HIV Drug Resistance

Collection Editor:

Prof. Dr. Hezhao Ji

National Microbiology
Laboratory at JC Wilt Infectious
Diseases Research Centre, Public
Health Agency of Canada,
Winnipeg, MB R3E 3R2, Canada

Message from the Collection Editor

Nearly four decades have passed since the human immunodeficiency virus (HIV) was identified as the causal agent for acquired immunodeficiency syndrome (AIDS); however, HIV/AIDS remains one of the leading causes of death. While a preventative HIV vaccine remains intangible, we have witnessed remarkable progress in the development of antiretroviral therapy (ART) since 1987. With over 50 drugs currently available and the global scaling up of ART, HIV/AIDS has been successfully converted from a fatal disease into a manageable chronic infection when effective ART is readily accessible. Despite this, HIV drug resistance (HIVDR) has long been a major obstacle hindering the maximization of the clinical benefits from ART. The notable increase in HIVDR prevalence, accompanying the global growth in ART usage, renders HIVDR an even more urgent issue to deal with for the sustainable reduction of HIV/AIDS-associated morbidity and mortality.

In this context, *Pathogens* has launched a thematic issue devoted to the “*Current Research on HIV Drug Resistance*”, aiming to publish the latest findings in this important research field. All submissions pertaining to HIVDR are welcome!





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Hinh Ly

Department of Veterinary &
Biomedical Sciences, University
of Minnesota, Twin Cities, MN,
USA

Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*General Immunology and Microbiology*)

Contact Us

Pathogens Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pathogens
pathogens@mdpi.com
[X@Pathogens_MDPI](https://twitter.com/Pathogens_MDPI)